Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group

References

• NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. J Am Med Assoc 1990;264:1444–50.
   PubMed Web of Science ®Google Scholar
• Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989; 7: 1447–56
   PubMed Web of Science ®Google Scholar
• Metzger U. Adjuvant therapy for colon and rectal cancer. NIH Consensus Development Conference. Eur J Cancer 1990; 26: 753–5
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–8
   PubMed Web of Science ®Google Scholar
• Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher ER, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP Protocol C-01. J Natl Cancer Inst 1988; 80: 30–6
   PubMed Web of Science ®Google Scholar
• Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. J Am Med Assoc 1988; 259: 3571–8
   PubMed Web of Science ®Google Scholar
• Quirt IC, Shelley WE, Pater JL, Bodurtha AJ, McCulloch PB, McPherson TA, et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: A phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1991; 9: 729–35
   PubMed Web of Science ®Google Scholar
• Schnall SF, Macdonald JS. Adjuvant therapy in colorectal carcinoma. Semin Oncol 1991; 18: 560–70
   PubMedGoogle Scholar
• Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991; 9: 736–40
   PubMed Web of Science ®Google Scholar
• Stevenson HC, Green I, Hamilton JM, Calabro BA, Parkinson DR. Levamisole: Known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol 1991; 9: 2052–66
   PubMed Web of Science ®Google Scholar
• Verhaegen H, De Cree J, De Cock W, Verhaegen-Declerq ML, Verbruggen F. Levamisole therapy in patients with colorectal cancer. Immunotherapy of Human Cancer. Rosenberg SA. New York: Elsevier; 1982. p 225–9.
   Google Scholar
• Windle R, Bell PRF, Shaw D. Five year results of a randomized trial of adjuvant 5fluorouracil and levamisole in colorectal cancer. Brit J Surg 1987; 74: 569–72
   PubMed Web of Science ®Google Scholar
• Arnaud JP, Buyse M, Adloff M, Nordlinger B, Pector JC, Duez N. Interim analysis of a double-blind phase-III clinical trial of adjuvant levamisole versus control in resectable Dukes-C colon cancer: A study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Rec Results Cancer Res 1988; 110: 101–3
   PubMedGoogle Scholar
• Pahlman L, Glimelius B. [Treatment of colorectal cancer with antineoplastic agents. Too early to introduce routine adjuvant therapy]. Lakartidningen 1991; 88: 208–9
   PubMedGoogle Scholar
• Glimelius B, Dahl O, Cedermark B, Jakobsen A, Bentzen SM, Starkhammar H, et al. Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 2005; 44: 904–12
   PubMed Web of Science ®Google Scholar
• Wibe A, Carlsen E, Dahl O, Tveit KM, Weedon-Fekjaer H, Hestvik UE, et al. Nationwide quality assurance of rectal cancer treatment. Colorectal Dis 2006; 8: 224–9
   PubMed Web of Science ®Google Scholar
• Wibe A, Møller B, Norstein J, Carlsen E, Wiig JN, Heald RJ, et al. A national strategic change in treatment policy for rectal cancer – implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 2002; 45: 857–66
   PubMed Web of Science ®Google Scholar
• Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much?. J Clin Oncol 2004; 22: 1797–806
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995; 13: 2936–43
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 1995; 122: 321–6
   PubMed Web of Science ®Google Scholar
• Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17: 3553–9
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Bermann A, Rettig K, Strohmeyer G, Porschen R. 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: Long-term follow-up results of the adjCCA-01 trial. Ann Oncol 2003; 14: 395–9
   PubMed Web of Science ®Google Scholar
• Au E, Ang PT, Seow-Choen F, Soo KC, Low CH, Chng HC, et al. Adjuvant chemotherapy for patients with resected Dukes' C and high-risk B2 colon cancer with fluorouracil and levamisole. Ann Acad Med Singapore 1998; 27: 733–7
   PubMedGoogle Scholar
• Benson AB, 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408–19
   PubMed Web of Science ®Google Scholar
• Marsoni S. Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Semin Oncol 2001; 28: 14–9
   PubMedGoogle Scholar
• Zaniboni A, Labianca R. Adjuvant therapy for stage II colon cancer: An elephant in the living room?. Ann Oncol 2004; 15: 1310–8
   PubMedGoogle Scholar
• Anonymous. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939–44.
   PubMedGoogle Scholar
• Anonymous. Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial. QUASAR Collaborative Group. Lancet 2000;355:1588–96.
   PubMedGoogle Scholar
• Francini G, Petrioli R, Lorenzini L, Mancini S, Armenio S, Tanzini G, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106: 899–906
   PubMed Web of Science ®Google Scholar
• Haller DG. An overview of adjuvant therapy for colorectal cancer. Eur J Cancer 1995; 31A: 1255–63
   PubMedGoogle Scholar
• Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 1349–55
   PubMed Web of Science ®Google Scholar
• O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246–50
   PubMed Web of Science ®Google Scholar
• Schippinger W, Jagoditsch M, Sorre C, Gnant M, Steger G, Hausmaninger H, et al. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. Br J Cancer 2005; 92: 1655–62
   PubMedGoogle Scholar
• Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. New Engl J Med 1985;312:1465–72.
   PubMed Web of Science ®Google Scholar
• Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. New Engl J Med 1991; 324: 709–15
   PubMed Web of Science ®Google Scholar
• Minsky BD. Adjuvant management of rectal cancer: The more we learn, the less we know. J Clin Oncol 2007; 25: 4339–40
   PubMedGoogle Scholar
• O'Neil BH, Tepper JE. Current options for the management of rectal cancer. Curr Treat Options Oncol 2007; 8: 331–8
   PubMedGoogle Scholar
• Sakamoto J, Ohashi Y, Hamada C, Buyse M, Burzykowski T, Piedbois P. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22: 484–92
   PubMed Web of Science ®Google Scholar
• Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007; 57: 168–85
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Mathur P, Elton C, Train ML. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of rectal cancer. Best Pract Res Clin Gastroenterol 2007; 21: 1049–70
   PubMedGoogle Scholar
• Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731–40
   PubMed Web of Science ®Google Scholar
• , Quasar Collaborative GroupGray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 2007;370:2020–9.
   PubMed Web of Science ®Google Scholar
• Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114–23
   PubMed Web of Science ®Google Scholar
• Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: Does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25: 4379–86
   PubMed Web of Science ®Google Scholar
• Berglund A, Cedermark B, Glimelius B. Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?. Ann Oncol 2008; 19: 400–2
   PubMed Web of Science ®Google Scholar
• Chau I, Norman AR, Cunningham D, Tait D, Ross PJ, Iveson T, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16: 549–57
   PubMed Web of Science ®Google Scholar
• Hershman D, Hall MJ, Wang X, Jacobson JS, McBride R, Grann VR, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 2006; 107: 2581–8
   PubMed Web of Science ®Google Scholar
• Andre T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: Final results of GERCOR C96.1. J Clin Oncol 2007; 25: 3732–8
   PubMed Web of Science ®Google Scholar
• Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, et al. Impact on survival of time from definite surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2006; 24: 4888–94
   PubMed Web of Science ®Google Scholar
• Elsaleh H. The microsatellite instability phenotype in human colorectal carcinoma: Relationship to sex, age and tumor site. Gastroenterology 2001; 121: 230–4
   PubMedGoogle Scholar
• Matanoski G, Tao XG, Almon L, Adade AA, Davies-Cole JO. Demographics and tumor characteristics of colorectal cancers in the United States, 1998-2001. Cancer 2006; 107: 1112–20
   PubMed Web of Science ®Google Scholar
• Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Assosiation of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355: 1745–50
   PubMed Web of Science ®Google Scholar
• Angell-Andersen E, Tretli S, Coleman MP, Langmark F, Grotmol T. Colorectal cancer survival trends in Norway 1958-1997. Eur J Cancer 2004; 40: 734–42
   PubMed Web of Science ®Google Scholar
• Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001; 44: 1682–8
   PubMedGoogle Scholar
• Fernandez E, Bosetti C, La Vecchia C, Levi F, Fioretti F, Negri E. Sex differences in colorectal cancer mortality in Europe, 1955-1996. Eur J Cancer Prev 2000; 9: 99–104
   PubMed Web of Science ®Google Scholar
• Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB, 3rd, Cummings B, et al. Adjuvant therapy in rectal cancer: Analysis of stage, sex, and local control–final report of intergroup 0114. J Clin Oncol 2002; 20: 1744–50
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343–51
   PubMed Web of Science ®Google Scholar
• Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 2007; 25: 2198–204
   PubMed Web of Science ®Google Scholar
• Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059–64
   PubMed Web of Science ®Google Scholar
• Twelves C, Wong A, Nowacki MP, Abt M, Burris H, 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696–704
   PubMed Web of Science ®Google Scholar
• Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 2007; 25: 3456–61
   PubMed Web of Science ®Google Scholar